Figure 3From: CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery OS (A) and PFS (B) durations were shorter in patients with a CA-125 level of > 1.68 × nadir at relapse than those in patients with a CA-125 level of ≤ 1.68 × nadir at relapse. Back to article page